[{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2024-07-02T16:35:09.543Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 01/10/2025","primary_completion_date":" 01/10/2025","study_txt":" Completion: 11/10/2025","study_completion_date":" 11/10/2025","last_update_posted":"2024-04-16"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"fe2e9c02-b568-4273-9f6b-89146f4af44d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756962","created_at":"2021-01-18T13:30:57.647Z","updated_at":"2024-07-02T16:35:12.037Z","phase":"Phase 2","brief_title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","source_id_and_acronym":"NCT02756962","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation","tags":["FLT3 • NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Rydapt (midostaurin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 07/06/2016","start_date":" 07/06/2016","primary_txt":" Primary completion: 07/31/2033","primary_completion_date":" 07/31/2033","study_txt":" Completion: 07/31/2033","study_completion_date":" 07/31/2033","last_update_posted":"2024-04-02"},{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2024-07-02T16:35:16.716Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation • CEBPA mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 05/30/2024","start_date":" 05/30/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-01"},{"id":"1c457901-9a43-4dcc-9740-e44b1b37ea65","acronym":"NCI-2018-03465","url":"https://clinicaltrials.gov/study/NCT03862157","created_at":"2021-01-18T19:03:08.762Z","updated_at":"2024-07-02T16:35:23.829Z","phase":"Phase 1/2","brief_title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT03862157 - NCI-2018-03465","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA","pipe":" | ","alterations":" NPM1 mutation • CEBPA mutation • PDGFRA rearrangement","tags":["ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CEBPA mutation • PDGFRA rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/27/2019","start_date":" 02/27/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"859b9a56-0db0-49fc-bcaf-d9e45201f632","acronym":"","url":"https://clinicaltrials.gov/study/NCT04415008","created_at":"2021-01-18T21:16:51.688Z","updated_at":"2024-07-02T16:35:34.633Z","phase":"Phase 2","brief_title":"Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT04415008","lead_sponsor":"wang, jianxiang","biomarkers":" CEBPA","pipe":" | ","alterations":" CEBPA mutation","tags":["CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-05"},{"id":"4636ef7a-95bb-4522-a60b-2fd02b36b883","acronym":"","url":"https://clinicaltrials.gov/study/NCT04173585","created_at":"2021-01-18T20:21:37.711Z","updated_at":"2024-07-02T16:35:52.203Z","phase":"Phase 2","brief_title":"TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib","source_id_and_acronym":"NCT04173585","lead_sponsor":"University Hospital Heidelberg","biomarkers":" FLT3 • CEBPA","pipe":" | ","alterations":" CEBPA mutation","tags":["FLT3 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2023-03-27"},{"id":"e1c7ba24-44af-4b89-9a62-1500c297696f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02722668","created_at":"2021-01-18T13:19:16.731Z","updated_at":"2024-07-02T16:35:54.803Z","phase":"Phase 2","brief_title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","source_id_and_acronym":"NCT02722668","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2023-02-24"},{"id":"89d88dc2-c1e4-4a45-b7f0-527d8736891a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01597778","created_at":"2021-01-18T06:49:49.857Z","updated_at":"2024-07-02T16:36:19.976Z","phase":"Phase 3","brief_title":"Double Cord Versus Haploidentical (BMT CTN 1101)","source_id_and_acronym":"NCT01597778","lead_sponsor":"Medical College of Wisconsin","biomarkers":" NPM1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 368","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 09/11/2020","primary_completion_date":" 09/11/2020","study_txt":" Completion: 09/11/2020","study_completion_date":" 09/11/2020","last_update_posted":"2021-12-01"},{"id":"8685c132-e923-4108-8205-2e1925660d94","acronym":"PCR-LMA","url":"https://clinicaltrials.gov/study/NCT04446741","created_at":"2021-01-18T21:23:54.145Z","updated_at":"2024-07-02T16:36:24.804Z","phase":"","brief_title":"Molecular Diagnostic Platform for AML","source_id_and_acronym":"NCT04446741 - PCR-LMA","lead_sponsor":"PETHEMA Foundation","biomarkers":" TP53 • FLT3 • IDH2 • NPM1 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • BRINP3 • SMC1A","pipe":" | ","alterations":" NPM1 mutation • U2AF1 mutation • CEBPA mutation","tags":["TP53 • FLT3 • IDH2 • NPM1 • RUNX1 • WT1 • CEBPA • PHF6 • RAD21 • BRINP3 • SMC1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • U2AF1 mutation • CEBPA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2021-09-06"},{"id":"c16de0cf-b9fe-4442-8cd2-246fe6771da8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01287104","created_at":"2021-01-18T05:13:27.987Z","updated_at":"2024-07-02T16:36:56.638Z","phase":"Phase 1","brief_title":"A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias","source_id_and_acronym":"NCT01287104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)","tags":["FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/29/2011","start_date":" 01/29/2011","primary_txt":" Primary completion: 06/28/2018","primary_completion_date":" 06/28/2018","study_txt":" Completion: 06/28/2018","study_completion_date":" 06/28/2018","last_update_posted":"2019-08-22"},{"id":"999d49d4-7e40-4fa2-9b64-3a59d2e91ecd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02118311","created_at":"2021-01-18T09:48:24.086Z","updated_at":"2024-07-02T16:37:15.936Z","phase":"Phase 2","brief_title":"Treg Cells for AGVHD in Non-myeloablative UCB Transplant","source_id_and_acronym":"NCT02118311","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • HLA-DRB1 • CEBPA • HLA-B","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • HLA-DRB1 • CEBPA • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2017-12-02"},{"id":"880f6a7c-6588-4f69-9ea9-e6700785e655","acronym":"","url":"https://clinicaltrials.gov/study/NCT01057199","created_at":"2021-01-18T04:09:44.689Z","updated_at":"2024-07-02T16:37:39.185Z","phase":"","brief_title":"Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01057199","lead_sponsor":"Children's Oncology Group","biomarkers":" CEBPA • MIR34A • E2F3 • MIR194","pipe":" | ","alterations":" CEBPA mutation • miR-34a overexpression • miR-34a underexpression","tags":["CEBPA • MIR34A • E2F3 • MIR194"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEBPA mutation • miR-34a overexpression • miR-34a underexpression"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 06/01/2010","primary_completion_date":" 06/01/2010","study_txt":" Completion: 06/01/2010","study_completion_date":" 06/01/2010","last_update_posted":"2015-05-07"}]